MERS
MCID: MDD018
MIFTS: 44

Middle East Respiratory Syndrome (MERS)

Categories: Infectious diseases, Rare diseases, Respiratory diseases

Aliases & Classifications for Middle East Respiratory Syndrome

MalaCards integrated aliases for Middle East Respiratory Syndrome:

Name: Middle East Respiratory Syndrome 12 58 15
Mers 58

Classifications:

Orphanet: 58  
Rare respiratory diseases
Rare infectious diseases


External Ids:

Disease Ontology 12 DOID:0080642
Orphanet 58 ORPHA576074

Summaries for Middle East Respiratory Syndrome

Disease Ontology : 12 A Coronavirus infection that is characterized by severe respiratory illness, including fever, cough, and shortness of breath and that has material basis in MERS-CoV.

MalaCards based summary : Middle East Respiratory Syndrome, also known as mers, is related to avian influenza and ebola hemorrhagic fever. An important gene associated with Middle East Respiratory Syndrome is DPP4 (Dipeptidyl Peptidase 4), and among its related pathways/superpathways are Measles and NF-kappaB Signaling. The drugs Remifentanil and Dexmedetomidine have been mentioned in the context of this disorder. Affiliated tissues include brain, kidney and t cells, and related phenotypes are cardiovascular system and immune system

Wikipedia : 74 Middle East respiratory syndrome (MERS), also known as camel flu, is a viral respiratory infection... more...

Related Diseases for Middle East Respiratory Syndrome

Diseases related to Middle East Respiratory Syndrome via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 189)
# Related Disease Score Top Affiliating Genes
1 avian influenza 30.7 ISG15 FURIN CXCL10
2 ebola hemorrhagic fever 30.6 IRF3 IFNB1 FURIN CXCL10
3 viral pneumonia 30.6 IFNB1 CXCL10 ACE2
4 vaccinia 30.5 ISG15 IRF3 IFNB1 CEACAM5
5 severe acute respiratory syndrome 30.4 TMPRSS2 TBK1 IRF3 IFNB1 IFIH1 FURIN
6 herpes simplex 30.3 TBK1 IRF3 IFNB1 IFIH1
7 mumps 30.1 IFNB1 FURIN CXCL10
8 influenza 30.1 TRIM25 TMPRSS2 ISG15 IRF3 IFNB1 IFIH1
9 covid-19 30.0 TMPRSS2 IFNB1 IFIH1 DPP4 CXCL10 ACE2
10 newcastle disease 29.9 IRF3 IFNB1 CXCL10
11 human immunodeficiency virus type 1 29.7 IRF3 HSPA5 DPP4 CXCL10 ADA
12 immune deficiency disease 29.4 TBK1 IFNB1 FURIN CXCL10 ADA
13 encephalitis/encephalopathy, mild, with reversible myelin vacuolization 11.1
14 disease by infectious agent 10.8
15 respiratory failure 10.7
16 pneumonia 10.6
17 adult respiratory distress syndrome 10.6
18 multinucleated neurons, anhydramnios, renal dysplasia, cerebellar hypoplasia, and hydranencephaly 10.5
19 diarrhea 10.5
20 thrombocytopenia 10.4
21 lung disease 10.3
22 neutropenia 10.3
23 acute kidney failure 10.3
24 measles 10.3
25 phlebotomus fever 10.3 IRF3 IFNB1
26 bladder tuberculosis 10.3 IFNB1 ADA
27 listeria meningitis 10.3 IFNB1 ADA
28 adult dermatomyositis 10.2 ISG15 IFIH1
29 helix syndrome 10.2
30 common cold 10.2
31 generalized anxiety disorder 10.2
32 post-traumatic stress disorder 10.2
33 bronchiolitis 10.2
34 kidney disease 10.2
35 lymphopenia 10.2
36 end stage renal disease 10.2
37 chronic kidney disease 10.2
38 cutaneous anthrax 10.2 FURIN ADA
39 splenic flexure cancer 10.2 DPP4 CEACAM5
40 herpangina 10.2 IRF3 IFNB1 IFIH1
41 west nile fever 10.2 IRF3 CXCL10
42 alk-negative anaplastic large cell lymphoma 10.2 DPP4 ADA
43 swine influenza 10.2 TRIM25 IRF3 IFNB1
44 vasculopathy, retinal, with cerebral leukoencephalopathy and systemic manifestations 10.2 TBK1 IRF3 IFIH1
45 hantavirus pulmonary syndrome 10.2 IRF3 IFNB1
46 pulmonary disease, chronic obstructive 10.1
47 disseminated intravascular coagulation 10.1
48 toxic shock syndrome 10.1
49 pulmonary tuberculosis 10.1
50 pulmonary fibrosis 10.1

Graphical network of the top 20 diseases related to Middle East Respiratory Syndrome:



Diseases related to Middle East Respiratory Syndrome

Symptoms & Phenotypes for Middle East Respiratory Syndrome

MGI Mouse Phenotypes related to Middle East Respiratory Syndrome:

46
# Description MGI Source Accession Score Top Affiliating Genes
1 cardiovascular system MP:0005385 9.85 ACE2 ADA CXCL10 DPP4 FURIN HSPA5
2 immune system MP:0005387 9.73 ACE2 ADA CXCL10 DPP4 FURIN IFIH1
3 respiratory system MP:0005388 9.17 ACE2 ADA DPP4 HSPA5 IRF3 PRKRA

Drugs & Therapeutics for Middle East Respiratory Syndrome

Drugs for Middle East Respiratory Syndrome (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 71)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Remifentanil Approved Phase 4 132875-61-7 60815
2
Dexmedetomidine Approved, Vet_approved Phase 4 113775-47-6 68602 5311068
3
Propofol Approved, Investigational, Vet_approved Phase 4 2078-54-8 4943
4 Adrenergic alpha-Agonists Phase 4
5 Anesthetics Phase 4
6 Analgesics, Non-Narcotic Phase 4
7 Hypnotics and Sedatives Phase 4
8 Narcotics Phase 4
9 Adrenergic Agents Phase 4
10 Anesthetics, Intravenous Phase 4
11 Analgesics Phase 4
12 Analgesics, Opioid Phase 4
13 Anesthetics, General Phase 4
14 Adrenergic Agonists Phase 4
15
Benzocaine Approved, Investigational Phase 2, Phase 3 1994-09-7, 94-09-7 2337
16
tannic acid Approved Phase 2, Phase 3 1401-55-4
17
Interferon beta-1b Approved Phase 2, Phase 3 145155-23-3
18
Ritonavir Approved, Investigational Phase 2, Phase 3 155213-67-5 392622
19
Lopinavir Approved Phase 2, Phase 3 192725-17-0 92727
20
Meropenem Approved, Investigational Phase 3 96036-03-2, 119478-56-7 64778 441130
21
Avibactam Approved Phase 3 1192500-31-4
22
Aztreonam Approved Phase 3 78110-38-0 5362041 5742832
23
Colistin Approved Phase 3 1066-17-7, 1264-72-8 5311054
24
Metronidazole Approved Phase 3 443-48-1 4173
25
Lenalidomide Approved Phase 3 191732-72-6 216326
26
Nafamostat Investigational Phase 2, Phase 3 81525-10-2
27 Cytochrome P-450 Enzyme Inhibitors Phase 2, Phase 3
28 Anti-HIV Agents Phase 2, Phase 3
29 Anti-Infective Agents Phase 2, Phase 3
30 Interferon-beta Phase 2, Phase 3
31 interferons Phase 2, Phase 3
32 Adjuvants, Immunologic Phase 2, Phase 3
33 Anti-Retroviral Agents Phase 2, Phase 3
34 Cytochrome P-450 CYP3A Inhibitors Phase 2, Phase 3
35 Antiviral Agents Phase 2, Phase 3
36 Immunosuppressive Agents Phase 2, Phase 3
37 Anti-Inflammatory Agents Phase 2, Phase 3
38 Anti-Inflammatory Agents, Non-Steroidal Phase 2, Phase 3
39 Complement System Proteins Phase 2, Phase 3
40 Anti-Infective Agents, Local Phase 2, Phase 3
41 Antirheumatic Agents Phase 2, Phase 3
42 Trypsin Inhibitors Phase 2, Phase 3
43 Immunologic Factors Phase 3
44 Angiogenesis Inhibitors Phase 3
45 Hematinics Phase 3
46 Epoetin alfa Phase 3 113427-24-0
47
Zoledronic Acid Approved Phase 2 118072-93-8 68740
48
Sodium citrate Approved, Investigational Phase 2 68-04-2
49
Citric acid Approved, Nutraceutical, Vet_approved Phase 2 77-92-9 311
50 Acyline Investigational Phase 1, Phase 2 170157-13-8

Interventional clinical trials:

(show all 31)
# Name Status NCT ID Phase Drugs
1 Effects of Anesthesia Drugs on Neuronal Activity in the Basal Ganglia and Thalamus During Deep Brain Stimulation Electrode Implantation Surgery Recruiting NCT03283150 Phase 4 Remifentanil;Propofol;Dexmedetomidine
2 Prospective, Multi-centre, Randomized, Parallel Comparison to Evaluate the Safety and Efficacy of the Abluminal Sirolimus Coated Bio-engineered Stent (COMBO Stent) in Association With Short-term Single Antiplatelet Therapy in Patients With Coronary Artery Disease With an Indication for Chronic Oral Anticoagulant Therapy as Compared to a Guidelines-based Strategy Withdrawn NCT02723981 Phase 4 Clopidogrel, Vitamin K Antagonist, Rivaroxaban, Dabigatran;ASA, Clopidogrel, Vitamin K Antagonist, Rivaroxaban, Dabigatran
3 MERS-CoV Infection tReated With A Combination of Lopinavir /Ritonavir and Interferon Beta-1b: a Multicenter, Placebo-controlled, Double-blind Randomized Trial Completed NCT02845843 Phase 2, Phase 3 Combination of Lopinavir /Ritonavir and Interferon beta-1b;Placebo
4 A PHASE 3 PROSPECTIVE, RANDOMIZED, MULTICENTER, OPEN-LABEL, CENTRAL ASSESSOR-BLINDED, PARALLEL GROUP, COMPARATIVE STUDY TO DETERMINE THE EFFICACY, SAFETY AND TOLERABILITY OF AZTREONAM-AVIBACTAM (ATM-AVI) ±METRONIDAZOLE (MTZ) VERSUS MEROPENEM±COLISTIN (MER±COL) FOR THE TREATMENT OF SERIOUS INFECTIONS DUE TO GRAM NEGATIVE BACTERIA, INCLUDING METALLO-Β-LACTAMASE (MBL) - PRODUCING MULTIDRUG RESISTANT PATHOGENS, FOR WHICH THERE ARE LIMITED OR NO TREATMENT OPTIONS Recruiting NCT03329092 Phase 3 ATM-AVI;MTZ;MER;COL
5 Rapid Experimental Medicine for COVID-19 - DEFINE COVID-19 Recruiting NCT04473053 Phase 2, Phase 3 Nafamostat Mesilate;TD139
6 Randomized Phase III Trial Comparing the Frequency of Major Erythroid Response (MER) to Treatment With Lenalidomide (Revlimid) Alone and in Combination With Epoetin Alfa (Procrit) in Subjects With Low- or Intermediate-1 Risk MDS and Symptomatic Anemia Active, not recruiting NCT00843882 Phase 3 Lenalidomide
7 Phase II Study to Assess the Safety, Imaging, Pharmacodynamic and Clinical Outcomes of Acute Ischemic Stroke Subjects Treated With tPA and THR-18 Unknown status NCT02572336 Phase 2 THR-18;Placebo;Tissue Plasminogen Activator (tPA)
8 Double-blind, Placebo-controlled, Escalating Single-dose, Phase 2a Study to Assess the Safety, Pharmacokinetics, and Pharmacodynamics of THR-18 in Subjects With Acute Ischemic Stroke and Treated With tPA Completed NCT01957774 Phase 2 THR-18;Placebo
9 Oral Administration of the GnRH Antagonist Acyline in Normal Men Part II: Multiple-dose Pharmacokinetics (Acyline-7/MER 104-02) Completed NCT00603187 Phase 1, Phase 2 Acyline
10 A Multi-Center Phase II Study to Compare MER-101 (20mg) Tablets To Intravenous Zometa 4mg in Male Bisphosphonate-Naive Hormone Refractory Prostate Cancer Patients Completed NCT00636740 Phase 2 Zoledronic Acid 20mg Tablets;Zoledronic Acid;Zoledronic Acid 20mg Tablets
11 Double-blind, Placebo-controlled Study With an Open Dose Selection Period for Assessing the Safety and Immunogenicity of the Drug "BVRS-GamVac", a Vector Vaccine for the Prevention of the Middle East Respiratory Syndrome, Lyophilisate for the Preparation of a Solution for Intramuscular Administration, With the Participation of Healthy Volunteers Recruiting NCT04130594 Phase 1, Phase 2
12 Double-blind, Placebo-controlled Study With an Open Dose Selection Period for Assessing the Safety and Immunogenicity of the Drug "BVRS-GamVac-Combi", a Combined Vector Vaccine for the Prevention of the Middle East Respiratory Syndrome, Lyophilisate for the Preparation of a Solution for Intramuscular Administration, With the Participation of Healthy Volunteers Recruiting NCT04128059 Phase 1, Phase 2 BVRS-GamVac-Combi
13 Study to Evaluate the Safety, Tolerability and Immunogenicity of INO-4700 for Middle East Respiratory Syndrome Coronavirus (MERS-CoV) in Healthy Volunteers Not yet recruiting NCT04588428 Phase 2 INO-4700;Placebo
14 Anti-MERS-COV Convalescent Plasma Therapy Withdrawn NCT02190799 Phase 2
15 A Phase Ib Study to Determine the Safety and Immunogenicity of the Candidate Middle East Respiratory Syndrome Coronavirus (MERS-CoV) Vaccine ChAdOx1 MERS in Healthy Adult Middle Eastern Volunteers Completed NCT04170829 Phase 1
16 An Open, Single Center Phase I Trial to Assess the Safety, Tolerability and Immunogenicity of Two Ascending Doses of the Candidate Vaccine MVA-MERS-S Completed NCT03615911 Phase 1
17 A Phase 1, Randomized Double-Blind, Placebo-Controlled, Single Ascending Dose Safety, Tolerability, and Pharmacokinetics Study of SAB-301 in Healthy Adults Completed NCT02788188 Phase 1
18 Extracorporeal Membrane Oxygenation Support for Middle East Respiratory Syndrome Induced Respiratory Failure Completed NCT02627378 Phase 1
19 A Phase I Trial to Evaluate the Safety, Tolerability, Pharmacokinetics and Immunogenicity of Co-administered MERS-CoV Antibodies REGN3048 and REGN3051 vs. Placebo in Healthy Adults Completed NCT03301090 Phase 1
20 A Phase I Study to Determine the Safety and Immunogenicity of the Candidate Middle East Respiratory Syndrome Coronavirus (MERS-CoV) Vaccine ChAdOx1 MERS in UK Healthy Adult Volunteers Recruiting NCT03399578 Phase 1
21 A Phase 1a/1b Study of OPT101 in Healthy Volunteers Recruiting NCT04589403 Phase 1 OPT101
22 A Two-center, Randomized, Double-blind, Placebo-controlled, Phase Ib Study to Assess the Safety, Tolerability and Immunogenicity of Two Ascending Doses of the Candidate Vaccine MVA-MERS-S_DF-1 in Healthy Study Subjects Not yet recruiting NCT04119440 Phase 1
23 Seroprevalence of IgG Antibodies to Middle East Respiratory Syndrome Coronavirus in Asymptomatic Healthcare Workers After Treatment of Confirmed MERS Patient Completed NCT02497885
24 Analysis of Human to Human Transmission of Middle East Respiratory Syndrom Coronavirus (MER-CoV) and Infection Control Experiences in a Medical Institution of South Korea Completed NCT02605109
25 The Merendino Procedure for Benign or Early Malignant Lesions of the Distal Esophagus/Gastroesophageal Junction is Feasible, Safe and Provides Good QoL Completed NCT02855333
26 Evaluation of Mer and Axl Expression in Acute Myeloid Leukemia Patient Samples Completed NCT01139333
27 Phase 0 Monitoring of Gluten-free Diet Compliance in Celiac Patients by Assessment of Gliadin 33-mer Equivalent Epitopes in Feces Completed NCT01478867
28 Incidence of Iatrogenic Diseases on Toulon-La Seyne Sur Mer Hospital Emergency Consultations During Summer 2018 Completed NCT03960398 Iatrogenic disease impact on emergency consultations
29 Badanie Kliniczne oceniające bezpieczeństwo i skuteczność Stosowania stentów Szyjnych MER® w Rewaskularyzacji tętnic Szyjnych. Completed NCT03133429
30 Detecting Soluble MER Levels After Myocardial Ischemia and Reperfusion Injury in Pediatric Patients Active, not recruiting NCT04322630
31 A Study of RXDX-106, an Oral Immunomodulatory TYRO3, AXL, and MER (TAM) Tyrosine Kinase Inhibitor, in Patients With Locally Advanced or Metastatic Solid Tumors Terminated NCT03454243 Early Phase 1 RXDX-106

Search NIH Clinical Center for Middle East Respiratory Syndrome

Genetic Tests for Middle East Respiratory Syndrome

Anatomical Context for Middle East Respiratory Syndrome

MalaCards organs/tissues related to Middle East Respiratory Syndrome:

40
Brain, Kidney, T Cells, Subthalamic Nucleus, Prostate, Eye, Heart

Publications for Middle East Respiratory Syndrome

Articles related to Middle East Respiratory Syndrome:

(show top 50) (show all 6288)
# Title Authors PMID Year
1
The interplay between emerging human coronavirus infections and autophagy. 61
33399028 2021
2
Repurposing existing drugs: identification of SARS-CoV-2 3C-like protease inhibitors. 61
33430659 2021
3
Food products as potential carriers of SARS-CoV-2. 61
33199941 2021
4
Mapping and role of T cell response in SARS-CoV-2-infected mice. 61
33464307 2021
5
Evolutionary dynamics of SARS-CoV-2 nucleocapsid protein and its consequences. 61
33095454 2021
6
Severe acute respiratory syndrome coronavirus 2 for physicians: Molecular characteristics and host immunity (Review). 61
33576464 2021
7
Interpretative immune targets and contemporary position for vaccine development against SARS-CoV-2: A systematic review. 61
33270225 2021
8
Airborne spread of infectious SARS-CoV-2: Moving forward using lessons from SARS-CoV and MERS-CoV. 61
33071145 2021
9
Epidemiology and pathobiology of SARS-CoV-2 (COVID-19) in comparison with SARS, MERS: An updated overview of current knowledge and future perspectives. 61
33462564 2021
10
Genomic and evolutionary comparison between SARS-CoV-2 and other human coronaviruses. 61
33290786 2021
11
sgRNACNN: identifying sgRNA on-target activity in four crops using ensembles of convolutional neural networks. 61
33385273 2021
12
Development and characterization of an indirect ELISA to detect SARS-CoV-2 spike protein-specific antibodies. 61
33412174 2021
13
Serological assays and host antibody detection in coronavirus-related disease diagnosis. 61
33492524 2021
14
The roles of signaling pathways in SARS-CoV-2 infection; lessons learned from SARS-CoV and MERS-CoV. 61
33462671 2021
15
An overview of Betacoronaviruses-associated severe respiratory syndromes, focusing on sex-type-specific immune responses. 61
33440306 2021
16
Review a brief history of coronaviruses in Thailand. 61
33285189 2021
17
The immune response and immune evasion characteristics in SARS-CoV, MERS-CoV, and SARS-CoV-2: Vaccine design strategies. 61
33429331 2021
18
Urogenital System Damaging Manifestations of 3 Human Infected Coronaviruses. 61
33026922 2021
19
Topological Analysis for Sequence Variability: Case Study on more than 2K SARS-CoV-2 sequences of COVID-19 infected 54 countries in comparison with SARS-CoV-1 and MERS-CoV. 61
33421654 2021
20
Comparison of the SARS-CoV-2 (2019-nCoV) M protein with its counterparts of SARS-CoV and MERS-CoV species. 61
33432259 2021
21
Real-time measurement of the uncertain epidemiological appearances of COVID-19 infections. 61
33519324 2021
22
COVID-19 and immunosuppression: a review of current clinical experiences and implications for ophthalmology patients taking immunosuppressive drugs. 61
32532764 2021
23
A review of potential suggested drugs for coronavirus disease (COVID-19) treatment. 61
33482181 2021
24
The prevalence of post-traumatic stress disorder related symptoms in Coronavirus outbreaks: A systematic-review and meta-analysis. 61
33433382 2021
25
Exploratory study on the spatial relationship between emerging infectious diseases and urban characteristics: Cases from Korea. 61
33520608 2021
26
Development of a SARS-CoV-2-specific biosensor for antigen detection using scFv-Fc fusion proteins. 61
33281048 2021
27
An overview of COVID-19 in people with diabetes: Pathophysiology and considerations in the inpatient setting. 61
33377213 2021
28
Learning from the past: development of safe and effective COVID-19 vaccines. 61
33067570 2021
29
A comparative study of human betacoronavirus spike proteins: structure, function and therapeutics. 61
33483791 2021
30
Impact of obesity on COVID-19 patients. 61
33358523 2021
31
Effect of different human tissue processing techniques on SARS-CoV-2 inactivation-review. 61
33033963 2021
32
Coronavirus biology and replication: implications for SARS-CoV-2. 61
33116300 2021
33
Coronavirus Receptors as Immune Modulators. 61
33380494 2021
34
Neurological manifestations of coronavirus disease 2019: exploring past to understand present. 61
33428055 2021
35
Immunoreactive peptide maps of SARS-CoV-2. 61
33580175 2021
36
Nucleoside Inhibitors of Coronaviruses. 61
33563148 2021
37
Possible transmission of viruses from contaminated human feces and sewage: Implications for SARS-CoV-2. 61
33022459 2021
38
The heterogeneous landscape and early evolution of pathogen-associated CpG dinucleotides in SARS-CoV-2. 61
33555346 2021
39
Exploring the efficacy of naturally occurring biflavone based antioxidants towards the inhibition of the SARS-CoV-2 spike glycoprotein mediated membrane fusion. 61
33571798 2021
40
Antigen-based multiplex strategies to discriminate SARS-CoV-2 natural and vaccine induced immunity from seasonal human coronavirus humoral responses. 61
33594376 2021
41
Potential drug targets of SARS-CoV-2: From genomics to therapeutics. 61
33577820 2021
42
Animal Coronaviruses and SARS-COV-2 in Animals, What Do We Actually Know? 61
33562645 2021
43
[Emotional management of the health crisis by coronavirus: A narrative review]. 61
32425490 2021
44
SARS-CoV-2: An Update on Genomics, Risk Assessment, Potential Therapeutics and Vaccine Development. 61
33567746 2021
45
Global patterns of recombination across human viruses. 61
33585889 2021
46
Hidden genomic diversity of SARS-CoV-2: implications for qRT-PCR diagnostics and transmission. 61
33602693 2021
47
Nanobodies, the potent agents to detect and treat the Coronavirus infections: A systematic review. 61
33358936 2021
48
SARS-CoV-2 infection is effectively treated and prevented by EIDD-2801. 61
33561864 2021
49
Neuroinvasive potential of SARS-CoV2 with neuroradiological and neuropathological findings: is the brain a target or a victim? 61
33098147 2021
50
Reversible splenial lesion syndrome associated with SARS-CoV-2 infection in two children. 61
33082059 2021

Variations for Middle East Respiratory Syndrome

Expression for Middle East Respiratory Syndrome

Search GEO for disease gene expression data for Middle East Respiratory Syndrome.

Pathways for Middle East Respiratory Syndrome

Pathways related to Middle East Respiratory Syndrome according to GeneCards Suite gene sharing:

# Super pathways Score Top Affiliating Genes
1
Show member pathways
12.27 TRIM25 TMPRSS2 TBK1 ISG15 IRF3 IFNB1
2 12.25 TRIM25 TBK1 IRF3 IFIH1 CXCL10 CEACAM5
3
Show member pathways
12.21 UBC TRIM25 ISG15 IRF3 IFNB1
4
Show member pathways
12.2 UBC TRIM25 TBK1 IRF3 IFNB1 IFIH1
5 12.12 UBC TBK1 IRF3 IFNB1
6
Show member pathways
11.72 UBC TRIM25 TBK1 ISG15 IRF3 IFNB1
7 11.15 ISG15 IFNB1 CXCL10
8 11.11 UBC TRIM25 IFIH1

GO Terms for Middle East Respiratory Syndrome

Cellular components related to Middle East Respiratory Syndrome according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 extracellular exosome GO:0070062 9.76 UBC TMPRSS2 HSPA5 FURIN DPP4 CTSL
2 extracellular region GO:0005576 9.61 TMPRSS2 ISG15 IFNB1 FURIN DPP4 CXCL10
3 cell surface GO:0009986 9.1 HSPA5 FURIN DPP4 CEACAM5 ADA ACE2

Biological processes related to Middle East Respiratory Syndrome according to GeneCards Suite gene sharing:

(show all 22)
# Name GO ID Score Top Affiliating Genes
1 proteolysis GO:0006508 9.99 TMPRSS2 FURIN DPP4 CTSL ACE2
2 innate immune response GO:0045087 9.97 TRIM25 TBK1 ISG15 IRF3 IFIH1
3 response to bacterium GO:0009617 9.77 ISG15 IRF3 CXCL10
4 viral process GO:0016032 9.76 TRIM25 TBK1 PRKRA ISG15 IRF3 IFIH1
5 viral entry into host cell GO:0046718 9.73 DPP4 CTSL ACE2
6 type I interferon signaling pathway GO:0060337 9.7 ISG15 IRF3 IFNB1
7 positive regulation of interferon-beta production GO:0032728 9.69 TBK1 IRF3 IFIH1
8 translesion synthesis GO:0019985 9.67 UBC TRIM25 ISG15
9 response to virus GO:0009615 9.65 TBK1 PRKRA IFNB1 IFIH1 CXCL10
10 zymogen activation GO:0031638 9.61 FURIN CTSL
11 response to vitamin D GO:0033280 9.58 TRIM25 CXCL10
12 TRIF-dependent toll-like receptor signaling pathway GO:0035666 9.58 UBC TBK1 IRF3
13 regulation of type I interferon production GO:0032479 9.57 TBK1 IRF3
14 positive regulation of type I interferon-mediated signaling pathway GO:0060340 9.55 TBK1 IRF3
15 modification-dependent protein catabolic process GO:0019941 9.54 UBC ISG15
16 positive regulation of interferon-alpha production GO:0032727 9.54 TBK1 IRF3 IFIH1
17 cellular response to exogenous dsRNA GO:0071360 9.5 IRF3 IFNB1 IFIH1
18 defense response to virus GO:0051607 9.5 TRIM25 TBK1 ISG15 IRF3 IFNB1 IFIH1
19 macrophage apoptotic process GO:0071888 9.48 IRF3 CTSL
20 MDA-5 signaling pathway GO:0039530 9.46 IRF3 IFIH1
21 regulation of cell-cell adhesion mediated by integrin GO:0033632 9.43 DPP4 ADA
22 negative regulation of type I interferon production GO:0032480 9.02 TRIM25 TBK1 ISG15 IRF3 IFIH1

Molecular functions related to Middle East Respiratory Syndrome according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 protease binding GO:0002020 9.43 UBC FURIN DPP4
2 peptidase activity GO:0008233 9.35 TMPRSS2 FURIN DPP4 CTSL ACE2
3 hydrolase activity GO:0016787 9.23 TMPRSS2 IFIH1 HSPA5 FURIN DPP4 CTSL
4 protein tag GO:0031386 9.16 UBC ISG15

Sources for Middle East Respiratory Syndrome

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
17 EFO
18 ExPASy
19 FMA
20 GARD
28 GO
29 GTR
30 HMDB
31 HPO
32 ICD10
33 ICD10 via Orphanet
34 ICD9CM
35 IUPHAR
36 KEGG
37 LifeMap
39 LOVD
41 MedGen
44 MeSH
45 MESH via Orphanet
46 MGI
49 NCI
50 NCIt
51 NDF-RT
53 NINDS
54 Novoseek
56 OMIM via Orphanet
57 OMIM® (Updated 05-Mar-2021)
61 PubMed
63 QIAGEN
68 SNOMED-CT via HPO
69 TGDB
70 Tocris
71 UMLS
72 UMLS via Orphanet
Content
Loading form....